InvestorsHub Logo
Followers 30
Posts 2777
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 121

Sunday, 05/15/2022 1:03:07 PM

Sunday, May 15, 2022 1:03:07 PM

Post# of 300
I agree. RHHBY's Genentech signed a deal with ADAP https://www.globenewswire.com/news-release/2021/09/07/2292303/35803/en/Adaptimmune-Enters-into-a-Strategic-Collaboration-with-Genentech-to-Research-Develop-and-Commercialize-Cancer-targeted-Allogeneic-T-cell-Therapies.html

Both are iPSC-derived, but the most interesting is the personalised therapy (targeting neoantigens) they are working on together.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DTIL News